The Imperative to Share Clinical Study Reports: Recommendations from the Tamiflu Experience

被引:126
作者
Doshi, Peter [1 ]
Jefferson, Tom [2 ]
Del Mar, Chris [3 ]
机构
[1] Johns Hopkins Univ, Sch Med, Baltimore, MD 21218 USA
[2] Cochrane Collaborat, Rome, Italy
[3] Bond Univ, Ctr Res Evidence Based Practice, Gold Coast, Australia
关键词
UPPER GASTROINTESTINAL TOXICITY; NEURAMINIDASE INHIBITORS; ADVISORY-COMMITTEE; ROSIGLITAZONE; ROFECOXIB; INFLUENZA; COMPLICATIONS; OSELTAMIVIR; NAPROXEN; SAFETY;
D O I
10.1371/journal.pmed.1001201
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页数:6
相关论文
共 44 条
  • [1] Abraham J., 1995, SCI POLITICS PHARM I
  • [2] [Anonymous], NY TIMES 1122
  • [3] [Anonymous], TAMIFLU CAPS CONS ME
  • [4] [Anonymous], OUTP EUR MED AG POL
  • [5] [Anonymous], 2007, WHO INT PROT RAP OP
  • [6] [Anonymous], SUMM PROD CHAR TAM 3
  • [7] [Anonymous], ROCH ANN NEW DAT REC
  • [8] [Anonymous], NY TIMES 0428
  • [9] [Anonymous], TAMIFLU DATA CALLED
  • [10] [Anonymous], GUID IND STRUCT CONT